BetterLife Pharma (BETRF) Cash from Operations (2010 - 2026)
BetterLife Pharma (BETRF) posted quarterly Cash from Operations of 174521.91 for Q2 2026, down 1643.41% year-over-year from 11307.54 in Q2 2025, and down 39.17% quarter-over-quarter from 125405.42 in Q3 2025.
BetterLife Pharma (BETRF) Cash from Operations (2010 - 2026) Analysis & Trends
BetterLife Pharma's Cash from Operations history runs 17 years deep, the most recent figure standing at 174521.91 for Q2 2026.
- In Q2 2026, Cash from Operations fell 1643.41% year-over-year to 174521.91; the TTM figure through Apr 2026 stood at 323454.95 (up 62.34% YoY), while the FY2026 annual figure was 450683.92, up 68.35% from the prior year.
- Cash from Operations for Q2 2026 stood at 174521.91, down from 125405.42 in the prior quarter.
- The five-year high for Cash from Operations was 10010.37 in Q2 2025, with the low at 1538887.82 in Q1 2022.
- The 5-year median for Cash from Operations is 272750.83 (2023), against an average of 394748.84.
- The sharpest annual moves came in 2025 and 2026: Cash from Operations surged 98.42% in 2025, then slumped 1643.41% in 2026.
- BetterLife Pharma's Cash from Operations stood at 477682.78 in 2022, then soared by 38.88% to 291953.18 in 2023, then surged by 64.38% to 104005.5 in 2024, then retreated by 20.58% to 125405.42 in 2025, then slumped by 39.17% to 174521.91 in 2026.
- Business Quant data shows BETRF's Cash from Operations at 174521.91 in Q2 2026, 125405.42 in Q3 2025, and 10010.37 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | BetterLife Pharma | 36.45 Mn | 36.42 Mn | - | -174,521.91 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -174,521.91 |
| Apr 30, 2026 | -174,521.91 |
| Jul 31, 2025 | -125,405.42 |
| Jul 31, 2025 | -125,405.42 |
| Apr 30, 2025 | -10,010.37 |
| Apr 30, 2025 | -10,010.37 |
| Jan 31, 2025 | -13,517.25 |
| Jan 31, 2025 | -13,517.25 |
| Oct 31, 2024 | -104,005.50 |
| Oct 31, 2024 | -104,005.50 |
| Jul 31, 2024 | -731,451.99 |
| Jul 31, 2024 | -731,451.99 |
| Apr 30, 2024 | -633,510.74 |
| Apr 30, 2024 | -633,510.74 |
| Jan 31, 2024 | -188,725.88 |
| Jan 31, 2024 | -188,725.88 |
| Oct 31, 2023 | -291,953.18 |
| Oct 31, 2023 | -291,953.18 |
| Jul 31, 2023 | -349,479.60 |
| Jul 31, 2023 | -349,479.60 |